Jiangsu, China

Kangning Zhan

This inventor holds 1 USPTO granted patent. Top assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kangning Zhan: Innovator in Medicinal Chemistry

Introduction

Kangning Zhan is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target specific biological pathways.

Latest Patents

Kangning Zhan holds 1 patent for his invention titled "Substituted tricyclic compound as PRMT5 inhibitor and use thereof." This patent pertains to a class of substituted tricyclic compounds that act as inhibitors of PRMT5, a protein implicated in various diseases. The invention provides a compound represented by a specific formula, along with its preparation method, pharmaceutical composition, and potential therapeutic applications for treating diseases mediated by PRMT5. The compounds demonstrate significant inhibitory activity on PRMT5, showcasing their potential in medicinal applications.

Career Highlights

Kangning Zhan is associated with Nanjing Sanhome Pharmaceutical Co., Ltd., where he continues to advance his research in medicinal chemistry. His work focuses on developing innovative solutions for complex medical challenges.

Collaborations

Kangning Zhan collaborates with esteemed colleagues such as Wei Sun and Guochuang Zheng, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Kangning Zhan's contributions to medicinal chemistry, particularly through his patented work, highlight his role as an influential inventor in the field. His ongoing research promises to impact the treatment of diseases mediated by PRMT5 significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…